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AKT-1The down-regulation or loss of epithelial markers is often accompanied by the up-regulation of mesen-
chymal markers. E-cadherin generally suppresses invasiveness, whereas N-cadherin promotes invasion
and metastasis in vitro. The aim of this work is to investigate the role of biﬂorin, a naphthoquinone with
proven anticancer properties, on the expression of N-cadherin and AKT proteins in MDA-MB-435 invasive
melanoma cancer cells after 12 h of exposure to 1, 2.5 and 5 lM biﬂorin. Biﬂorin inhibited MDA-MB-435
invasion in a dose-dependent manner (p < 0.01). Likewise, biﬂorin down-regulated N-cadherin and AKT-1
expression in a dose-dependent manner. Biﬂorin did not inhibit the adhesion of MDA-MB-435 cells to any
tested substrates. Additionally, biﬂorin blocked the invasiveness of cells by down-regulating N-cadherin,
most likely via AKT-1 signaling. As such, biﬂorin may be a novel anticancer agent and a new prototype for
drug design.
 2013 Elsevier Ltd. All rights reserved.1. Introduction
Most cancer deaths are due to the development of metastases
and/or the failure of therapeutic regimens (Zhou et al., 2008; Chu
et al., 2007). Melanoma is the most invasive and deadly form of
skin cancer. Patients with advanced melanoma with dissemination
to distant organs have very poor prognosis, with a median survival
time of only 6–9 months and a 3-year survival rate of only 10–15%
(Eggermont and Robert, 2012; Balch et al., 2009; Sharma et al.,
2009).
Most anticancer drugs are generally aimed to inhibit cell
growth to slow the growth of the primary tumor or to reduce the
existing tumor burden. For several decades, no substantial progress
has been made in developing effective drugs for treating patients
with advanced-stage melanoma (Atallah and Faherty, 2005; Pérez
and Danishefsky, 2007). Recent insights into melanoma biology has
resulted in effective immunotherapy and targeted therapy, such as
ipilimumab, an anti-CTLA-4 monoclonal antibody, and vemurafe-
nib, a BRAF inhibitor, which are changing the treatment paradigm
for metastatic melanoma (Graziani et al., 2012; Chapman et al.,2011). However, as observed in patients with other tumors, pa-
tients undergoing immunotherapy and/or targeted therapy usually
develop resistance after a period of time. Thus, the approach to
treat any type of cancer should be to target a biological network,
not just a single molecule (Shuptrine et al., 2012). As a direct result
of the lack of effective therapeutics, the prognosis for patients with
metastatic disease remains very poor. Thus, the use of agents that
inhibit metastasis could be effective, in combination with current
drugs, to prevent the migration, invasion or colonization of the pri-
mary tumor cells at other sites of the body.
To invade, cancer cells of epithelial origin have to migrate from
the primary tumor mass by breaking their cell–cell contacts,
known as adherens junctions (Hazan et al., 2004; Makrilia et al.,
2009). The cell adhesion molecule, E-cadherin, a cell-surface pro-
tein that accounts for cell-to-cell or cell-to-extracellular matrix
(ECM) interactions, is usually absent or dysfunctional in most of
the advanced, undifferentiated and aggressive breast and other
epithelial carcinomas. This is usually associated with poor patient
prognosis (Gupta et al., 2006). Moreover, the loss of E-cadherin in
tumor cells confers an invasive or metastatic phenotype (Onder
et al., 2008). In tumor cells, the gain of expression of another adhe-
sion molecule, N-cadherin, has been associated with increased
invasive potential (Nieman et al., 1999; Hulit et al., 2007; Hazan
et al., 2000; Rieger-Christ et al., 2004). Previous studies have
Fig. 1. Chemical structure of biﬂorin (6,9-dimethyl-3-(4-methyl-3- pentenyl)naph-
tha[1,8-bc]-pyran-7,8-dione).
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cer cell lines that lacks E-cadherin (Nieman et al., 1999) and that it
elicits bladder cell invasion in vitro (Rieger-Christ et al., 2004).
The down-regulation or loss of epithelial markers, such as E-
cadherin, is accompanied by the up-regulation of mesenchymal
markers, such as N-cadherin and vimentin (Yang et al., 2006). This
process is called the epithelial to mesenchymal transition (EMT)
and is known to enhance cell motility. As such, E-cadherin gener-
ally suppresses invasiveness, whereas N-cadherin promotes inva-
sion and metastasis in vitro (Nieman et al., 1999; Hazan et al.,
2000).
Multiple factors can induce and regulate the motility oftumor
cells, there by contributing to invasion. It has been suggested that
the expression of N-cadherin is sufﬁcient to trigger EMT, at least by
the activation of PI3-K/Akt pathway (Rieger-Christ et al., 2004). The
Akt family of kinases, i.e., Akt1, Akt2, and Akt3, plays arolein pro-
cesses that are well known as hallmarks of cancer, such as sus-
tained angiogenesis, unlimited replicative potential, and tissue
invasion and metastasis (Hanahan andWeinberg, 2011). Moreover,
Akt activation mediates the expression of N-cadherin and metallo-
proteinases and plays aroleintum or invasion and metastasis by
inducing EMT (Park et al., 2001; Higuchi et al., 2001; Grille et al.,
2003; Wallerand et al., 2010). Recently, Steelman et al. (2011)
demonstrated that the activation of AKT-1 increased the resistance
of MCF-7 cells to radiation. Additionally, Toker and Yoeli-Lerner
(2006) showed that Akt1 might have a dual role in tumorigenesis,
not only promoting it by suppressing apoptosis but also inhibiting
it by suppressing invasion and metastasis.
The speciﬁc role of AKT in terms of cell motility and invasion
seems to depend on the cell type and the pathways that are acti-
vated. Many of the enzymes that either mediate the Akt signal,
such as MDM2 (Zhou et al., 2001), or regulate Akt activity, such
as the tumor suppressor PTEN (Li et al., 1997), are frequently mu-
tated in human tumors. As such, Akt activity is up-regulated, thus
increasing tumor cell growth and survival. In several mammalian
systems, activated Akt1 correlates with cell migration and inva-
sion. While constitutively active Akt1 can enhance the ability of
some cells to invade (Steelman et al., 2011; Kim et al., 2001; Arbol-
eda et al., 2003), Akt1 can also have the opposite effect in normal or
less invasive cells (Arboleda et al., 2003). Moreover, the increased
activation of Akt1 correlates with increased proliferation and
anchorage-independent growth. However, the effects of activated
Akt1 on cell migration and invasiveness depend on the type of cells
and tissues in which its action is being studied (Steelman et al.,
2011; Kim et al., 2001; Arboleda et al., 2003; Enomoto et al.,
2005; Irie et al., 2005; Yoeli-Lerner et al., 2005). Yoeli-Lerner
et al. (2005) and Toker and Yoeli-Lerner (2006) revealed that the
expression of activated Akt1 potently blocks the migration and
invasion of three distinct breast cancer cell lines through Matrigel
in vitro. In ﬁbroblasts, Akt signaling enhances the activation of var-
ious small GTPases, leading to remodeling of the actin cytoskeleton
and enhancing cell motility (Enomoto et al., 2005). Similarly, the
expression of activated Akt in ﬁbrosarcoma or pancreatic cancer
cells increases their ability to invade through Matrigel (Park
et al., 2001; Kim et al., 2001). Liu et al. (2006) demonstrated that
cells expressing activated Akt1 show increased proliferation and
resistance to apoptosis. Additionally, the invasiveness and motility
of the cells were substantially decreased by the down-regulation of
Rho activity. Moreover, AKT1 deletion markedly delayed murine
breast tumor formation driven by activated RAS (Skeen et al.,
2006). Although the expression of activated AKT1 accelerates
HER-2/NEU-driven breast tumor formation, the tumors that devel-
oped were highly differentiated, poorly invasive, and rarely metas-
tasized (Hutchinson et al., 2004). AKT1 also plays a prominent role
in tumor angiogenesis. Normal endothelial cells with sustained
activation of AKT1 develop the complex structural and functionalabnormalities that are characteristic of tumor blood vessels (Phung
et al., 2006). These results reinforce the idea that an understanding
of cell- and tissue-speciﬁc signaling pathways is critical for evalu-
ating the implications of activated upstream signaling molecules
on complex phenotypic effects.
Until now, despite large research efforts in targeting tumor
metastasis, no progress has been achieved in efﬁciently preventing
metastasis (Christofori, 2006). This might be due to the mecha-
nisms involved in cell migration, which can be reprogrammed,
thus allowing the cells to maintain their invasive properties via
morphological and functional de-differentiation.
Natural products have been remarkable source for new antican-
cer drugs. Biﬂorin (Fig. 1), an ortho–naphthoquinone, can be iso-
lated from the roots of Capraria biﬂora L. (Schrophulariaceae),a
perennial shrub that was originally found in the Antilles and South
America (Acosta et al., 2003). This quinone has been shown to have
anticancer properties in vitro and in vivo, increasing the survival of
mice with melanoma tumors, without diminishing the tumor size
(Vasconcellos et al., 2005, 2007, 2011). As such, the aim of this
work is to investigate the role of biﬂorin in MDA-MB-435, an inva-
sive melanoma cancer cell, in vitro.2. Material and methods
2.1. Cell lines, antibodies, and reagents
The MDA-MB-435 (human melanoma), MCF-10A (normal hu-
man breast) and melan-A (normal mouse melanocyties) cell lines
were obtained from American Type Culture Collection (ATCC). All
the cell lines were cultured according to ATCC recommendations.
The following reagents were used: mouse monoclonal anti-N-cad-
herin AB-2 (Cell Signaling), mouse monoclonal anti-b-actin (Cell
Signaling), and Super Signal West Pico Chemiluminescent kit
(Pierce). Etoposide, dimethyl sulfoxide, paraformaldehyde, and
crystal violet were purchased from Sigma–Aldrich. Alamar Blue
was purchase from Invitrogen. The invasion plates were obtained
from Corning.
2.2. In vitro studies
Cell viability assays.
2.2.1. Alamar Blue assay
MDA-MB-435 cells were seeded in 96-well plates at a density of
104 cells per well. They were treated with biﬂorin, and the Alamar
BlueTM assay was performed (Ahmed et al., 1994) after 8, 12, and
24 h. After the cells were allowed to attach for 24 h, biﬂorin (0.1,
0.5, 1, 5 and 10 lM) was dissolved in dimethyl sulfoxide (DMSO)
and added to each well, and the cells were incubated for 8, 12
and 24 h. Etoposide (10, 20 and 50 lM) was used as positive con-
trol. Control groups received the same amount of DMSO (0.1%).
One hour before the end of the incubations, 20 lL of Alamar Blue™
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using a multiplate reader using an excitation wavelength of 530–
560 nm and an emission wavelength of 590 nm. The ﬂuorescent
signal generated from the assay was taken to be proportional to
the number of living cells in the sample, as stated by the
manufacturer.2.2.2. Trypan blue exclusion
Cell viability and death was determined by the trypan blue as-
say (Louis and Siegel, 2011). Cells were seeded in a 12-well plate at
a density of 2  105 cells per well. After 24 h, they were treated
with biﬂorin at 1, 2.5 and 5 lM. Aliquots from each well were re-
moved from the cultures after 8, 12, 24 h of incubation, stained
with 0.4% trypan blue and counted with the Countess™ automated
cell counting platform from Invitrogen. The staining was used to
quantify the number of living cells in the samples.2.2.3. Crystal violet stain
Cells were seeded in 12-well plates at a density of 2  105 cells
per well and treated with biﬂorin at 1, 2.5 and 5 lM. After 12 h of
incubation, the cells were washed with phosphate buffered saline
(PBS), and ﬁxed in 4% paraformaldehyde for 30 min at 4 C. The
cells were then washed three times with distilled water, and
0.1% crystal violet was added to each well. They were then incu-
bated for 20 min at room temperature. The plates were washed
with distilled water to remove excess dye and then dried at room
temperature. The plates were scanned and the intensity of the
stained wells was obtained.2.3. Cell-substrate adhesion assays
For the cell adhesion assay, 96-well plates (Nunc, Roskilde)
were coated with Fibronectin, type I and IV collagen by incubating
the dishes overnight at 4 C. Any uncoated surfaces of the dishes
were blocked by the addition of 2% bovine serum albumin (BSA)
(RIA grade; Sigma), which was also used as a negative control.
The unbound ECM substrates were removed and the coated dishes
were blocked with BSA for 1 h at 37 C. Then, the dishes were
washed with PBS and media was added before the cells were pla-
ted. The MDA-MB 435 cells treated with 1, 2.5 and 5 lM biﬂorin
were trypsinized, and 4  105 cells were plated into each well.
After incubation at 37 C for 2 h, the nonattached cells were re-
moved and the remaining cells that were attached were ﬁxed with
PHA, washed, and stained with crystal violet. The absorbance was
measured at 570 nm. Each panel is representative of duplicate
experiments conductedin triplicate.2.4. Invasion assay
In vitro invasion assays were performed using modiﬁed Boyden
chambers consisting of transwell membrane ﬁlter inserts (8 lm
pore size; Corning Costar Corp., Cambridge, MA, USA) placed in
24-well tissue culture plates. The upper surfaces of the membranes
were coated with Matrigel and placed into 24-well tissue culture
plates containing 600 lL of conditioned DMEMmedia (experimen-
tal) or non-conditioned DMEM (control). The cells were seeded in
p100 plates (2  105 cells/mL) and treated with biﬂorin at 1, 2.5
and 5 lM. After 8 h of treatment, the cells were trypsinized,
counted and added to each transwell chamber. They were then al-
lowed to invade towards the underside of the membrane for 4 h at
37 C. The cells that passed through the membrane were ﬁxed in
methanol, stained with crystal violet and counted under a light
microscope. All assays were performed in duplicate.2.5. Molecular biology studies
2.5.1. Western blotting
The cells were washed twice with ice-cold PBS and lysedon ice
for 30 min in lysis buffer (100 mmol/L sodium orthovanadate,
100 mmol/L NaF, 20 mmol/L HEPES (pH 7.5), 150 mmol/L NaCl,
1.5 mmol/L MgCl2, 5 mmol/L sodium pyrophosphate, 10% glycerol,
0.2% Triton X-100, 5 mmol/LEDTA, 1 mmol/L phenylmethylsulfonyl
ﬂuoride, 10 lg/mL leupeptin, and 10 lg/mL aprotinin). The lysates
were clariﬁed by centrifugation at 14,000 g for 10 min at 4 C.
Equal amounts of protein were subjected to SDS–PAGE and trans-
ferred tonitrocellulose membranes (Amersham Pharmacia Bio-
tech). The membranes were blocked with 5% nonfat milk in TBS-
Tween 20 for 1 h at room temperature and then probed with pri-
mary antibodies overnight at 4 C. After incubation with horser
adish peroxidase–conjugated secondary antibodies, the immuno-
reactive bands were visualized using the Super Signal West Pico
Chemiluminescent kit (Pierce). Three independent experiments
were performed to analyze the protein levels.
2.5.2. Real-time PCR
Total RNA was extracted from MDA-MB-435 cells with the
RNeasy Mini Kit (Qiagen).Single-stranded cDNA was constructed
using Superscript III polymerase (Invitrogen) and oligo-dT primers.
Real-time polymerase chain reaction (RT-PCR)was performed using
theMyIQ (Bio-Rad) and SYBRGreen PCRmaster-mix reagents (USB).
The following primers were used: AKT-1 forward 50-ATGGCACCTT-
CATTGGCTAC-30 and reverse 50-AAGGTGCGTTCGATGACAGT-30.
2.6. Statistical analysis
The data are presented as the mean ± SEM. The differences be-
tween the experimental groups were compared by analysis of var-
iance (ANOVA), followed by Dunnett’s Multiple Comparison Test
(p < 0.05) using the GRAPHPAD program (Intuitive Software for Sci-
ence, San Diego, CA, USA).
3. Results
3.1. Biﬂorin was not cytotoxic towards MDA-MB-435 cancer cells and
MCF10-A and Melan-A normal cell lines in vitro
MDA-MB-435, an invasivemelanoma cancer cell line, was treated
with increasing concentrations of biﬂorin, 5, 10 and 20 lM, for 24, 48
and 72 h and analyzed by the Alamar Blue™ assay. A signiﬁcant sup-
pression of cell growth was observed in the presence of biﬂorin
(Fig. 2A). To determine the concentration and time required for biﬂo-
rin to inhibit the invasion ofMDA-MB-435 cells in theMatrigelmodel
without killing the cells, decreased concentrations of biﬂorin, 0.1, 0.5,
1.0 and 5 lM, were tested for 8, 12 and 24 h and analyzed using the
Alamar Blue™assay (Fig. 2B). No cytotoxicity was observed for all
tested concentrations at 8 and 12 h. For both experiments, 10, 20
and 50 lM etoposide were used as positive controls.
All subsequent experiments were performed in MDA-MB-435
cancer cells after 12 h of incubation with 1, 2.5 and 5 lM biﬂorin.
To access cell viability, two models were used, direct cell counting
by trypan blue exclusion and colony staining by crystal violet dye.
The results indicated that biﬂorin did not alter the viability of all
three cell lines in all tested concentrations after 12 h of treatment
(p > 0.05) (Fig. 3A–F).
3.2. Biﬂorin inhibits the invasion, but not the adhesion, of MDA-MB435
melanoma cancer cells in vitro
Cell invasion is one of the steps involved in metastasis. To deter-
mine whether biﬂorin was involved in this process, the authors
Fig. 2. Biﬂorin inhibit MDA-MB-435 melanoma cell growth. (a) Biﬂorin inhibits cell
growth at all tested concentration and time course (p < 0.05). Etoposide used as a
positive control inhibit cell growth at all tested concentration, however only after
48 and 72 h (p < 0.05). Mean values of three independent measurements (±SD) are
shown. (b) Biﬂorin did not inhibit cell growth after 8 and 12 h at all tested
concentration. Only after 24 h, biﬂorin inhibit cell growth at 5 lM. Etoposide did
not inhibit cell growth. Mean values of three independent measurements (±SD) are
shown. ANOVA followed by Tukey’s test.
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cell death. Thus, the viability of MDA-MB-435 melanoma cancer
cells was assessed after 8 and 12 h of treatment with 1, 2.5 and
5 lM biﬂorin. As shown in Fig. 3C, cell death was not observed in
any of the concentrations of biﬂorin and durations of incubation
tested. However, a strong and dose-dependent reduction in the
invasion of MDA-MB-435 cells through the Matrigel matrix was
observed after the treatment with 1, 2.5 and 5 lM biﬂorin
(38.25 ± 9.53; 16.5 ± 3.31 and 2.25 ± 0.95, respectively).In compar-
ison, this was not observed in the negative control (55.00 ± 3.9)
(Fig. 4A and B). Additionally, biﬂorin did not inhibit the adhesion
of MDA-MB-435 cells to any of the ECM substrates tested (data
not shown).3.3. Biﬂorin inhibits invasion by down-regulating N-cadherin and AKT-
1
The cadherins are a family of a cell to cell adhesion molecules
that have been implicated in the invasive process (Hanahan and
Weinberg, 2011). To determine whether the inhibition of invasion
by biﬂorin was related to N-cadherin protein levels, a western blot
was performed. After 12 h of biﬂorin treatment, the protein levels
of N-cadherin were down-regulated in a dose dependent manner
(Fig. 4C and D). To further understand the signaling pathways in-
volved in the inhibition of invasion, the expression levels of AKT-
1 was assessed. 36B4, acidic ribosomal phosphoprotein P0, was
used as a reference gene. AKT-1mRNA levels were down-regulated
in a dose-dependent manner by 94.65, 76.25 and 21.35%, by 1, 2.5
and 5 lM biﬂorin, respectively (Fig. 4E). After 12 h of treatmentwith 5 lM biﬂorin, the AKT-1 (p < 0.05) mRNA level was decreased
by 5-fold (p < 0.05).4. Discussion
Melanoma is one of the most invasive and deadly forms of skin
cancer, and only a few agents are available for treating advanced
disease to enable long-term patient survival. However, these
agents are relatively ineffective, with overall response rates of 5–
20%. This ﬁnding supports the need for identifying new compounds
that inhibit the pathways that are deregulated in melanoma
(Eggermont and Robert, 2012; Sharma et al., 2009).
Anticancer drug development strategies are usually aimed at di-
rectly inhibiting the growth of the primary tumor or reducing the
existing tumor burden. Therapeutic agents that can inhibit metas-
tasis could be an option for preventing colonization, thereby en-
abling the containment of the primary tumors in a chemically
manageable form (Pérez and Danishefsky, 2007; Hedley et al.,
2004).
In this study, using melanoma cell lines as a model for invasion
studies, we investigated the ability of biﬂorin, an ortho-naphtho-
quinone, to treat solid tumors. We also investigated the EMC sub-
strates, Fibronectin and types I and IV collagen, and the expression
of N-cadherin and AKT1.
The MDA-MB-435 cell line is a controversial invasive cancer cell
line because, for several decades, it was considered to be a breast
cancer cell line (Chambers, 2009). However, gene expression proﬁl-
ing showed that it expressed both epithelial and melanocytic
markers, and as such, the National Cancer Institute (NCI) now con-
siders it to be a melanoma cell line (Garraway et al., 2005). Regard-
less of its origin, the MDA-MB-435 cell line is an aggressive cell line
that can be used as a model to study invasion in vitro (Hulit et al.,
2007).
Biﬂorin has been shown to be cytotoxic to cancer cell lines
in vitro and in vivo (Vasconcellos et al., 2005, 2007, 2011, 2010). Re-
cently, Vasconcellos et al. (2011) described that biﬂorin inhibits
several melanoma cell lines in vitro. Moreover, biﬂorin inhibited
DNA synthesis, leading to the apoptosis of B16, a murine mela-
noma cell line (Vasconcellos et al., 2011). Biﬂorin also increased
survival rates and inhibited tumor growth in an in vivo melanoma
B16 model (Vasconcellos et al., 2011). These results supported
gaining an understanding of the mechanisms behind biﬂorin activ-
ity in cancer cells.
Here, we described that biﬂorin inhibits MDA-MB-435 cell inva-
sion in vitro in a dose-dependent manner. The MDA-MB-435 cell
line expresses genes associated with both breast cancer and mela-
noma. For this reason, the authors conducted the experiments on
normal cell lines of both breast and melanocyteorigin, MCF-10A
and Melan-A, respectively. However, at all concentrations tested,
biﬂorin had no effect on the normal cell lines. Vasconcellos et al.
(2010) demonstrated that at lower concentrations, biﬂorin hadsig-
niﬁcant antioxidant and protective effects against cytotoxicity,
genotoxicity, mutagenicity, and intracellular lipid peroxidation in-
duced by H2O2 in yeast and normal mammalian cells. This result
could be attributed to its hydroxyl radical-scavenging property
and corroborated our ﬁndings. However, at higher concentrations,
biﬂorin was cytotoxic and genotoxic.
Many changes in gene expression and protein functions occur
during tumor progression. Alterations in cell–cell and cell-matrix
adhesion seem to have a central role in facilitating the migration,
invasion and metastatic dissemination of tumor cells (Yilmaz and
Christofori, 2010). Multiple cell adhesion molecules, such as
E- and N-cadherin, which are calcium-dependent cells adhesion
molecules that mediate homophilic cell–cell adhesion, have been
reported to play roles in melanoma progression. The cadherin
Fig. 3. Biﬂorin did not inhibit cell growth at 12 h treatment. (a and b) Results of MCF-10A cell viability. (c and d) Results of Melan-A cell viability. (e and f) Results of MDA-
MB-435 cell viability; all evaluated by the trypan blue and crystal violet, respectively. Three independent experiments were performed in triplicate (mean ± SE). No signiﬁcant
differences were observed for all cells treated with biﬂorin at 12 h. ANOVA followed by Tukey’s test.
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of melanoma cells and promotes the invasion of melanoma cells
(Hsu et al., 2000). The pro-invasive action of N-cadherin persisted
even in the presence of E-cadherin, suggesting that N-cadherin has
a dominant effect over the normally tumor-suppressive E-cad-
herin, (Nieman et al., 1999; Hazan et al., 2000). Additionally, N-
cadherin plays a role in the formation and stability of blood vessels
(Paik et al., 2004), which are processes that are important for tu-
mor growth (Naumov et al., 2008).
It is well known that N-cadherin is upregulated in invasive tu-
mor cell lines and in tissues from melanomas, breast and prostate
cancers (Hazan et al., 1997).Inhibitors of N-cadherin function have
been demonstrated to cause apoptosis in certain cell types (Erez
et al., 2004), and drugs targeting N-cadherin may thus have multi-
ple therapeutic applications.
The MDA-MB-435 cell line over expresses N-cadherin, but it
does not express E-cadherin. As such, it is a suitable model forstudying processes related to cell motility, invasion and metastasis
(Nieman et al., 1999). In our model, biﬂorin decreased the expres-
sion of N-cadherin in a dose-dependent manner, thus accounting
for its inhibitory effect on invasion. Our results are supported by
those of Lee et al. (1998). As such, we propose that the effect of
biﬂorin on the invasiveness of this cell line is most likely due to
its action on the expression of N-cadherin. These results may ex-
plain the increased survival in mice treated with biﬂorin that
was observed by Vasconcellos et al. (2011). Given the results ob-
tained so far, we propose a mechanism underlying biﬂorin action
(Fig. 5).
N-cadherin antagonists have shown promise as anti-cancer
agents in pre-clinical and clinical trials (Lyon et al., 2010; Beasley
et al., 2009). One of the major issues to be resolved is why N-cad-
herin antagonists, such as ADH-1 and anti-N-cadherin Mabs, are
not toxic, given the wide distribution of this cell adhesion molecule
(CAM) (Blaschuk, 2012). This is also the case for biﬂorin because no
Fig. 4. Biﬂorin interaction impacts on invasive activity of melanoma cells via modulating N-cadherin and AKT-1 expression in vitro. (a) Representative images of the
Transwell assays of MDA-MB-435 cell invasion. Magniﬁcation 40 (1-control, 2–1.0 lM, 3–2.5 lM, 4–5.0 lM). (b) Results of Transwell assays showed the relative number of
invasive MDA-MB-435 cells with indicated treatments after 12 h. Three independent experiments were performed in triplicate (mean ± SE). p < 0.01. (c) Expression of N-
cadherin in melanoma cells was detected by Western blotting after 12 h. Three independent experiment were performed. (d) N-cadherin protein densitometry. Four
independent experiment were performed. p < 0.05. ANOVA follow by Tukey’s. (e) Real time RT-PCR results of mRNA expression of AKT-1 in melanoma cells treated with
biﬂorin after 12 h. Three independent experiments were performed in triplicate (mean ± SE). p < 0.05. ANOVA followed by Tukey’s test.
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inhibitor or drug lead.
It has been suggested that the expression of N-cadherin is suf-
ﬁcient to trigger EMT, at least in part, by the activation of the
PI3-K/Akt pathway (Rieger-Christ et al., 2001). Moreover, N-cad-
herin and phospho-EGFR expression have been associated with
Akt activation and with the modulation of invasiveness (Wallerand
et al., 2010).
AKT is a serine-threonine kinase whose isoforms, AKT1, AKT2,
and AKT3, exist in mammalian cells. These play roles in processes
that are considered hallmarks of cancer, such as unlimited replica-
tive potential, sustained angiogenesis, tissue invasion and metasta-
sis (Hanahan and Weinberg, 2011).
A functional role for Akt in cell motility was ﬁrst reported by
Meili et al. (1999). Servant et al. (2000) subsequently demon-
strated similar effects in neutrophils. Although both AKT1 andAKT2 have a role in cell motility and invasion, distinct and even
opposing functions have been described for these proteins. In some
cell systems, AKT1 enhances cell invasion and migration. In others,
AKT1 inhibits motility, while AKT2 promotes motility (Vasko et al.,
2004). Moreover, Akt1 nullﬁbroblasts have been shown to be less
motile and invasive when compared to control ﬁbroblasts (Irie
et al., 2005; Yoeli-Lerner et al., 2005; Vasko et al., 2004). Both
AKT1 and AKT2 were found to enhance the invasiveness of human
pancreatic cancer cells, raising the possibility that the effects of
Akt1 on invasiveness and motility are cell type speciﬁc (Skeen
et al., 2006). In vivo studies in which tumor formation is reduced
by crossing mice into an Akt1-deﬁcient background support these
observations (Saji et al., 2005). Our results suggest that the inhibi-
tion of invasion of the MDAMB-435 melanoma cell line by biﬂorin
is due to the down-regulation of N-cadherin, which inhibits AKT1
expression. This observation is in agreement with several other
Fig. 5. The down-regulation or loss of epithelial markers is accompanied by
mesenchymal markers neoexpression. E-cadherin generally suppresses invasive-
ness, whereas N-cadherin promotes invasion and metastasis in vitro. Biﬂorin is a
naphthoquinone with proven anticancer properties. In this way, the aim of this
work is to investigate the role of biﬂorin in MDA-MB-435 invasive melanoma
cancer cell and the N-cadherin protein status. Biﬂorin inhibited MDA-MB-435
invasion in a dose- dependent manner (p < 0.01). Likewise, biﬂorin down-regulated
N-cadherin and AKT-1 expression in a dose-dependent manner. Biﬂorin did not
inhibit MDA-MB-435 cell adhesion to all tested substrate. Biﬂorin can be a
prototype to new anticancer drugs design.
2082 R.C. Montenegro et al. / Toxicology in Vitro 27 (2013) 2076–2083studies (Steelman et al., 2011; Vasko et al., 2004; Saji et al., 2005)
that have reported that AKT1 promotes motility in different cell
lines. Thus, its inhibition could abolish cell invasion, as was ob-
served in our model. These observations are particularly important,
given the development of both generalized and isoform-speciﬁc
Akt inhibitors for clinical trials.
In summary, to our knowledge, this is the ﬁrst mechanistic
explanation for how biﬂorin, a natural compound, abrogates inva-
sion. We showed that in MDA-MB-435 melanoma cells, this most
likely occurs by the inhibition of N-cadherin and the AKT-1 path-
way. Further animal and iRNA studies have to be performed to fully
elucidate the mechanisms underlying the biological actions of
biﬂorin.
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